Association between comorbidities and major adverse cardiovascular events in patients undergoing immune checkpoint blockade

Further Publications

Real-world burden of cardiovascular events following immune checkpoint inhibitor therapy: impact on mortality and treatment resumption in 29,503 patients

Lung Cancer

Rigaux C, Arangalage D, Adkins K, Illiano S

doi: 10.1016/j.lungcan.2026.109499

Lung, Respiratory and Thoracic Cancer

Pretreatment eosinophilia as a biomarker for adverse outcomes in non-small cell lung cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis

Semin Oncol

Ganatra N, Thompson J, Desai R, Doshi J, Jain P, Pasnoor DS, Jain A

doi: 10.1016/j.seminoncol.2025.152431

Further Publications

Immune Checkpoint Inhibitor-Associated Cardiovascular Toxic Effects: International Cardio-Oncology Society Position Statement

JAMA Oncol

Herrmann J, Barac A, Carver J, Cheng RK, Daniele A, Dent S, Deych E, Lee DH, Lenihan D, Leong DP, Liu J, Lopez-Fernandez T, Lyon AR, Fradley M, Macedo AVS, Mooradian MJ, Nohria A, Porter C, Rassaf T, Suero-Abreu G, Sverdlov AL, Thavendiranathan P, Neilan TG, Mitchell JD

doi: 10.1001/jamaoncol.2025.4543

Further Publications

Immune thrombocytopenia in patients treated with immune checkpoint inhibitors

Blood

Leaf RK, Mones JV, Shenoy T, Warsame M, Beltrami-Moreira M, Panch S, Leavitt AD, Zon RL, Kendall EK, Shahamatdar S, Lim TL, Cui C, Jiang D, Kaunfer SA, Durai L, Hoge ST, Dias JA, Sha C, Holmes A, Easton N, Corley E, Zhao E, Li X, Spelman A, Amos CB, Soebbing DR, Shabih M, Jamison T, Liu B, Hussein G, Yadav SK, Elsaid MI, Owen DH, Mera A, Juras PK, Suresh A, Heskel MJ, Huang JJ, Glezerman I, Go RS, Reynolds K, Al-Samkari H, Kroll MH, Leaf DE

doi: 10.1182/blood.2025031449

Multiple Myeloma (MM)

Cardiovascular complications and their association with short- and long-term outcomes in patients with multiple myeloma undergoing chimeric antigen receptor T-cell therapy

Br J Haematol

Itzhaki Ben Zadok O, Simitsis P, Jacobson C, Nadeem O, Frigault MJ, Raje N, Duffy C, Costello P, Cruz JD, Looka A, Nohria A

doi: 10.1111/bjh.70216

Further Publications

Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 patients

Clin Cancer Res

Sato T, Butler MO, Piperno-Neumann S, Hassel JC, Nathan P, Shoushtari AN, Rutkowski P, Carvajal RD, Baurain JF, Schlaak M, Piulats JM, Sullivan RJ, Ochsenreither S, Dummer R, Kirkwood JM, Ikeguchi A, Joshua AM, Middleton MR, Edukulla R, Pfeiffer C, Sacco JJ

doi: 10.1158/1078-0432.CCR-25-1513

Lymphoma

Real-world patient-reported symptomatic adverse events and concordance with physician assessments after CAR T-cell therapy in patients with aggressive B-cell lymphomas: a prospective study

Lancet Haematol

Efficace F, Zinzani PL, Bonifazi F, Cutini I, Botto B, Chiappella A, Tisi MC, Bramanti S, Puglia S, Tartaglia F, Donzelli L, Farina M, Martino M, Gambella M, Ragaini S, Orciuolo E, Martelli M, Corradini P, Fazi P, Vignetti M, Rocco AD

doi: 10.1016/S2352-3026(26)00128-6

SPECIAL REPORT

Lung, Respiratory and Thoracic Cancer

COCOON Study: Enhanced dermatologic management reduces dermatologic adverse events with amivantamab plus lazertinib in patients with NSCLC harboring common EGFR mutations*

Lung, Respiratory and Thoracic Cancer

Immune checkpoint inhibitor-induced interstitial lung disease with and without CTLA-4 regimen in non-small cell lung cancer patients and PD-L1

Lung Cancer

Murata D, Azuma K, Murotani K, Ito K, Nomizo T, Yamada K, Imabayashi T, Iwanaga K, Chibana K, Ota T, Nishii Y, Nakao A, Okada A, Hamai K, Tanimura K, Yoshimine K, Tamura Y, Takaki R, Goto Y, Hibino M, Oba T, Sumi T, Kaneda H, Nishioka N, Yamada T, Takayama K

doi: 10.1016/j.lungcan.2025.108772

Related content

Real-world burden of cardiovascular events following immune checkpoint inhibitor therapy: impact on mortality and treatment resumption in 29,503 patients

Pretreatment eosinophilia as a biomarker for adverse outcomes in non-small cell lung cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis

Immune Checkpoint Inhibitor-Associated Cardiovascular Toxic Effects: International Cardio-Oncology Society Position Statement

Immune thrombocytopenia in patients treated with immune checkpoint inhibitors

Cardiovascular complications and their association with short- and long-term outcomes in patients with multiple myeloma undergoing chimeric antigen receptor T-cell therapy

Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 patients

Real-world patient-reported symptomatic adverse events and concordance with physician assessments after CAR T-cell therapy in patients with aggressive B-cell lymphomas: a prospective study

COCOON Study: Enhanced dermatologic management reduces dermatologic adverse events with amivantamab plus lazertinib in patients with NSCLC harboring common EGFR mutations*

Immune checkpoint inhibitor-induced interstitial lung disease with and without CTLA-4 regimen in non-small cell lung cancer patients and PD-L1